Will the new multiple sclerosis drug Antegren be the next blockbuster drug as some analysts predict? Cormac Sheridan investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ciric, B. et al. J. Neuroimmunol. 146, 153–161 (2004).
Yednock, T.A. et al. Nature 356, 63–66 (1992).
Youssef, S. et al. Nature 420, 78–84 (2002).
Vollmer, T. et al. Lancet 363, 1607–1608 (2004).
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Sheridan, C. Fast track to MS drug. Nat Biotechnol 22, 939–941 (2004). https://doi.org/10.1038/nbt0804-939
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0804-939
This article is cited by
-
Tysabri raises alarm bells on drug class
Nature Biotechnology (2005)
-
Tysabri withdrawal calls entire class into question
Nature Medicine (2005)
